A Study to Evaluate the Superiority, Efficacy and Tolerability of Combination Pantovigar With 2% Minoxidil vs 2% Minoxidil in Women With Female Pattern Hair Loss

Inclusion Criteria: * Female patient complaint of hair loss and/or hair density reduction for more than 3 months. * More than 15 % of telogen frontoparietal hair as shown in the phototrichogram. Exclusion Criteria: * Symptomatic diffuse alopecia (screening for iron and thyroid function, thyroid stimulating hormon, triiodothyrine, ferritin , total iron-binding capacity) * Active or history of systemic autoimmune disease, e.g. lupus erythematodes etc. * Hyperandrogenic alopecia (polycystic ovary syndrome, adrenogenital syndrome, tumors with androgenic activity) (testosterone, prolactin hormone, androstenedione, dehydroepiandrosterone) * Initiation or termination of hormone therapy within 6 months prior to entering study * Hormone therapy with androgenic action, e.g. norethisterone etc. * Pregnancy or lactation within 6 months prior to entering study * Alopecia areata * Scarring alopecia * Treatment with hair promoting agent within 3 months prior to entering study * Known hair loss after drug intake * Concomitant use of the drugs causing a hair loss (e.g. aromatase inhibitors, thyreostatics, cytostatics, etc,)